|
|
Post by lojothehus on Sept 13, 2017 16:45:02 GMT -5
1. An announcement of a label change 2. A partnership with Merck 3. An deal overseas 4. Finally, a substantial increase in script numbers
All of these dreams could very well come true this Friday. What are your 4 dreams that may come true? |
|
|
|
Post by nemzter on Sept 13, 2017 17:05:50 GMT -5
5. Buyout announcement by Amgen
|
|
|
|
Post by nylefty on Sept 13, 2017 17:36:15 GMT -5
5. Buyout announcement by Amgen No! That would be bad news for me. Any possible buyout price at this point would be far too low. |
|
|
|
Post by sportsrancho on Sept 13, 2017 18:04:38 GMT -5
1. An announcement of a label change 2. A partnership with Merck 3. An deal overseas 4. Finally, a substantial increase in script numbers
All of these dreams could very well come true this Friday. What are your 4 dreams that may come true? I'm with you:-) A full label change on all counts. Partnership with Merck with up front payment good for 18 months runway. A payment from Dubai:-) And big jump in scripts! |
|
|
|
Post by dg1111 on Sept 13, 2017 19:34:22 GMT -5
This is sort where we've been for a couple years. Any day sales can take off, a Technosphere licensing deal can be announced, international expansion can start.
With respect to Technosphere and international Afrezza sales, I do wonder what deals we have turned down.
|
|
|
|
Post by qwertqwert on Sept 13, 2017 19:49:34 GMT -5
Wait, is it Christmas eve tomorrow?
|
|
|
|
Post by dreamboatcruise on Sept 13, 2017 20:00:26 GMT -5
1) An attractive house guest serving me breakfast in bed
2) A winning lottery ticket
2) Peace on earth
3) A non dilutive financing that gets us at least 6 months additional burn
We can wish.
I'd be happy with a sales number at least as high as last week. Tickled pink by sales greater than 2 weeks ago (post Sanofi high). So deliriously happy that I'd nearly faint if we hit a sales number higher than Sanofi's all time high.
|
|
|
|
Post by dreamboatcruise on Sept 13, 2017 20:04:46 GMT -5
5. Buyout announcement by Amgen No! That would be bad news for me. Any possible buyout price at this point would be far too low. We're playing make believe, so it can be a buyout price that would never really happen. But yes, I'd be one sad lizard if we get bought out now. Of course that would be within the context of not knowing whether the only other option would have been worse. |
|
|
|
Post by mytakeonit on Sept 13, 2017 22:40:19 GMT -5
You all sound like lottery players. I'm a blackjack player and more realistic. I go for things that are more attainable ... anything more is a bonus.
So ... What are your 4 dreams that may come true?
I'll go with 4 wet dreams.
|
|
|
|
Post by mango on Sept 13, 2017 22:52:08 GMT -5
1. The Afrezza VW bus 2. Changing the Standards of Care 3. Changing the Standards of Care 4. The answer to the ultimate question of life, the universe, and everything Future daily driver  |
|
|
|
Post by boytroy88 on Sept 14, 2017 1:34:29 GMT -5
1. The Afrezza VW bus 2. Changing the Standards of Care 3. Changing the Standards of Care 4. The answer to the ultimate question of life, the universe, and everything ----->  ?Future daily driver |
|
|
|
Post by mnholdem on Sept 14, 2017 8:49:47 GMT -5
1. An announcement of a label change 2. A partnership with Merck 3. An deal overseas 4. Finally, a substantial increase in script numbers
All of these dreams could very well come true this Friday. What are your 4 dreams that may come true? I'm with you:-) A full label change on all counts. Partnership with Merck with up front payment good for 18 months runway. A payment from Dubai:-) And big jump in scripts! Here's just one example of what could happen (this PR was released this morning):
DJ Halozyme's Stock Soars After Bristol-Myers License Deal -- MarketWatch
Shares of Halozyme Therapeutics Inc. (HALO) rocketed 13% in premarket trade Thursday, after the biotechnology company announced a license agreement with Bristol-Myers Squibb Co. (BMY), to develop subcutaneously administered Bristol-Myers immuno-oncology medicines using Halozyme's drug-delivery technology. Under terms of the deal, Halozyme will receive $105 million upfront, will have the potential to earn up to an additional $160 million in milestone payments and will receive royalties on sales of products. As of result of the deal, Halozyme raised its 2017 revenue outlook to $245 million to $260 million from $115 million to $130 million.
---
As I posted in another thread, if the rumor about Merck is true, I expect a license agreement for development of drug using MannKind's drug delivery technology vs. a buy out of Technosphere as some suggest.
|
|
|
|
Post by aliceliter on Sept 14, 2017 9:49:20 GMT -5
Speaking of Amgen, I was working on one of their new building back in the late 80's. This was before they had any drugs approved. Still remember the day in Oct. when the market tanked. There stock was 20 buck a share. Thought about buying but I just bought a new car. 1000 shares would now be 24000 shares. I think I screwed up.
By the way, holding MNKD, 17000. And believe it or not I am actually in the green.
Good luck to all. |
|
|
|
Post by dh4mizzou on Sept 14, 2017 9:52:45 GMT -5
1. The Afrezza VW bus 2. Changing the Standards of Care 3. Changing the Standards of Care 4. The answer to the ultimate question of life, the universe, and everything -----> ?Future daily driver Beat me to it ;-) |
|
|
|
Post by babaoriley on Sept 14, 2017 18:23:34 GMT -5
1. An announcement of a label change 2. A partnership with Merck 3. An deal overseas 4. Finally, a substantial increase in script numbers
All of these dreams could very well come true this Friday. What are your 4 dreams that may come true? You may get all those things just before you wake up, lojo...  |
|
